Technology Commercialization Office

Showing 44 result(s) for "Therapeutics"

Novel in-vivo mice models facilitating the study of pancreatic beta cell loss and corresponding type one diabetes as well as other pancreatic diseases.

Inhibition of two members of the miRNA 17~92 cluster as a potential cystic fibrosis therapy. Our in vivo data using CF mouse model demonstrate that targeting Mir17 and Mir20 improves autophagy and bacterial clearance. Targeting these 2 Mirs also improves the function of the CFTR channel in cells expressing F508del mutation which is the most common mutation in CF patients.

An antitumor agent developed from indol-3-carbinol, a naturally ocurring phytochemical in crucifeous vegetables.

An Estrogen Receptor Beta Agonist for the treatment of breast, colon, and prostate cancers as well as inflammatory diseases.

Exosome system that utilizes miRNA to selectively target cells or tissues for the delivery of therapeutic nucleic acid sequences.

Identified gene target for treatment of human acute leukemia, brain tumors and melanomas.

A method using sub-millimeter sized microcapsules to guide the assembly of endothelial or endothelial progenitor cells to form 3D microcapillary in 3D engineered tissue under ultra-low attachment culture condition.

An activator that could potentially treat cancer and aberrant metabolic conditions.

Exposing cancer cells to poor cell adhesion environments via small molecule agents as a strategy to improve clinical outcomes of several solid malignancies.

Several methods for generating polyaniline and its derivative nanofibers